TD Cowen reiterated its Buy rating and $20.00 price target for EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT). This aligns with the broader analyst consensus, as InvestingPro data shows analyst targets ...
EyePoint (EYPT) stock rose 10% after the company reported six-month results from a phase 2 study of its drug Duravyu in the treatment of diabetic macular edema. Read more here.
Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...
Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...
February 4, 2025) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between November 2, 2023 and ...
Continuous Glucose Monitor Data Predicts Type 1 Diabetes Complications Jan. 15, 2025 — Data from continuous glucose monitors can predict nerve, eye and kidney damage caused by type 1 diabetes ...
EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...
After repeatedly wowing investors, Roche’s star eye med Vabysmo collected more than $4 billion in sales during its third year ...
In October, Oxular began a phase 2 trial for its therapeutic candidate OXU-001, for treatment of diabetic macular edema ...
It might sound silly, but my under-eye area is where I can feel dryness the most, and eye creams and masks save my skin time and time again. As with any beauty product, there are always a few ...
In fact, 8 mg is estimated to remain in the eye for 6 weeks longer ... longer acting agents is that they may extend the time between injections compared to current treatment options. With Eylea 2 mg, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback